Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2008-04-08
2008-04-08
Minnifield, Nita (Department: 1645)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S045000, C514S046000, C514S047000, C514S048000, C536S023100, C536S025100, C536S025300, C536S025600
Reexamination Certificate
active
07354907
ABSTRACT:
The invention relates to modulation of the immune system. More particularly, the invention relates to modulating the immune system through the use of oligonucleotide-derived compounds. The invention provides immunostimulatory agents that are less expensive to make than existing immunostimulatory oligonucleotides. The immunostimulatory agents according to the invention can, in preferred embodiments, cause immune stimulation across species lines.
REFERENCES:
patent: 5366878 (1994-11-01), Pederson et al.
patent: 5635377 (1997-06-01), Pederson et al.
patent: 5856462 (1999-01-01), Agrawal
patent: 5968909 (1999-10-01), Agrawal et al.
patent: 6426334 (2002-07-01), Agrawal et al.
patent: 6815429 (2004-11-01), Agrawal
patent: 7276489 (2007-10-01), Agrawal et al.
patent: 2003/0129605 (2003-07-01), Yu et al.
patent: 2004/0097719 (2004-05-01), Agrawal et al.
patent: 2004/0152649 (2004-08-01), Krieg
patent: 2004/0156825 (2004-08-01), Agrawal et al.
patent: 2004/0198685 (2004-10-01), Agrawal et al.
patent: 2004/0266710 (2004-12-01), Kandimalla et al.
patent: 2005/0009773 (2005-01-01), Kandimalla et al.
patent: 2005/0026858 (2005-02-01), Kandimalla et al.
patent: 2005/0026861 (2005-02-01), Kandimalla et al.
patent: 2005/0130918 (2005-06-01), Agrawal et al.
patent: 2005/0222072 (2005-10-01), Wang et al.
patent: 2006/0014713 (2006-01-01), Agrawal et al.
patent: 2007/0173469 (2007-07-01), Agrawal et al.
patent: 2007/0219153 (2007-09-01), Kandimalla et al.
patent: 1393745 (2004-03-01), None
patent: WO 98/49288 (1998-11-01), None
patent: WO 01/12804 (2001-02-01), None
patent: WO 01/55370 (2001-08-01), None
patent: WO 01/83503 (2001-11-01), None
patent: WO 02/26757 (2002-04-01), None
patent: WO 03/057822 (2003-07-01), None
patent: WO 2004/064782 (2004-08-01), None
Bhagat et al, BBRC, Jan. 24, 2003, 300/4:853-861.
Yu et al, Nucleic Acid Research, Oct. 15, 2002, 30/20:4460-4469.
Yu et al, BBRC, 2002, 297:83-90.
Yu et al, Bioorganic & Medicinal Chemistry Letters, 2000, 10:2585-2588.
Zhao et al, Bioorganic & Medicinal Chemistry Letters, 2000, 10:1051-1054.
McCluskie et al, Vaccine, 2001, 19:413-422.
Li et al, International Immunopharmacology, 2005, 1:981-991.
Kandimalla et al, PNAS, Nov. 25, 2003, 100/24:14303-14308.
Marshall et al, Nucleic Acids Research, 2003, 31/17:5122-5133.
Zhu et al, International Immunopharmacology, 2004, 4:851-862.
Kandimalla et al, Nucleic Acids Research, 2003, 31/9:2393-2400.
Kandimalla et al, Bioconjungate Chem., 2002, 13:966-974.
Kandimalla et al, Current Opinion in Molecular Therapeutics, 2002, 4/2:122-129.
Yu et al, Bioorganic & Medicinal Chemistry Letters, 2001, 11:2263-2267.
Kandimalla et al, Bioogranic & Medicinal Chemistry, 2001, 9:807-813.
Zhao et al, Bioorganic & Medicinal Chemistry Letters, 1999, 9:3453-3458.
Agrawal et al, Current Opinion in Biotechnology, 1995, 6:12-19.
McCluskie et al, FEMS Immunology and Medical Microbiology, 2002, 32:179-185.
Yu et al, Bioorganic & Medicinal Chemistry, 2001, 9:2803-2808.
Zhao et al, Biochemical Pharmacology, 1996, 51/2:173-182.
Zhao et al, Biochemical Pharmacology, 1996, 52/10:1537-1544.
Klinman et al, Drug News Perspect, Jun. 2000, 13/5:289-296.
Agrawal et al, Current Cancer Drug Targets, 2001, 1:197-209.
Tokunaga et al, J. Natl. Cancer Inst. 72 :955-962 (1984).
Yamamoto et al., Jpn. J. Cancer Res. 79 : 866-873 (1988).
Messina et al., J. Immunol. 147: 1759-1764 (1991).
Tokunaga et al., Microbiol. Immunol. 36: 55-66 (1992).
Yamamoto et al, J. Immunol. 148; 4072-4076 (1992).
Krieg et al., Nature 374: 546-549 (1995).
Halpern et al., Cell Immunol., 167: 72-78 (1996).
Klinman et al., Proc. Natl. Acad. Sci. U.S.A. 93: 2879-2883 (1996).
Liang et al., J. Clin. Invest. 98: 1119-1129 (1996).
Sato et al, Science 273 : 352-354 (1996).
Zhao et al., Antisense Nucleic Acid Drug Dev. 7: 495-502 (1997).
Hartmann et al., J. Immunol. 164: 1617-1624 (2000).
Yu et al., “Immunomers—Novel 3′-3′-Linked CpG Oligodeoxyribonucleotides as Potent Immunomodulatory Agents”, Nucleic Acids Research, 30(20):4460-4469 (2002).
Yu et al., “Potent CpG Oligonucleotides Containing Phosphodiester Linkages: In Vitro and In Vivo Immunostimulatory Properties”, Biochem. And Biophsy. Res. Comm., 297:83-90 (2002).
Bhagat et al., “CpG Penta- and Hexaddeoxyrobonucleotides as Potent Immunomodulatory Agents”, Biochem. And Biophsy. Res. Comm., 300(4):853-861 (2003).
Kandimalla et al., “Divergent Synthetic Nucleotide Motif Recognition Pattern: Design and Development of Potent Immunomodulatory Oligodeoxyribonucleotide Agents with Distinct Cytokine Induction Profiles”, Nuc. Acids. Res., 31(9):2393-2400 (2003).
Li et al., “Oligodeoxynucleotides Containing Synthetic Immunostimulatory Motifs Augment Potent Th1 Immune Responses to HbsAg in Mice”, Int'l. Immunopharmacology, 5:981-991 (2005).
Zhu et al., “Modulation of Ovalbumin-Induced Th2 Response by Second-Generation Immunomodulatory Oligonucleotides in Mice”, Int'l. Immunopharmacology, 4:851-862 (2004).
Klinman et al., “Therapeutic Applications of CpG-Containing Oligodeoxynucleotides”, Antisense & Nucleic Acid Drug Development, 8:181-184 (1998).
Zhao et al., “Immunostimulatory Activity of CpG Containing Phosphorothioate Oligodeoxynucleotide is Modulated by Modification of a Single Deoxynucleotide”, Bioorg. & Med. Chem. Lett., 10:1051-1054 (2000).
Kandimalla et al., “Towards Optimal Design of Second Generation Immunomodulatory Oligonucleotides”, Curr. Opin. Mol. Therap., 4(2):122-129 (2002).
Yu et al., “Accessible 5′-End of CpG-Containing Phosphorothioate Oligodeoxynucleotides is Essential for Immunostimulatory Activity”, Bioorg. & Med. Chem. Lett., 10:1585-2588 (2000).
Marshall et al., “Novel Chimeric Immunomodulatory Compounds Containing Short CpG Oligodeoxyribonucleotides Have Differential Activities in Human Cells”, Nucleic Acids Res., 31(17):5122-5133 (2003).
Kandimalla et al., “Conjugation of Ligands at the 5′-End of CpG DNA Affects Immunostimulatory Activity”, Biocon. Chem., 13:966-974 (2002).
Kandimalla et al., “A Dinucleotide Motif is Oligonucleotides Shows Potent Immunomodulatory Activity and Overrides Specie-Specific Recognition Observed with CpG Motif”, 100(24):14303-14308 (2003).
Agrawal Sudhir
Bhagat Lakshmi
Kandimalla Ekambar R.
Yu Dong
Idera Pharmaceuticals Inc.
Keown & Zucchero, LLP
Minnifield Nita
LandOfFree
Short immunomodulatory oligonucleotides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Short immunomodulatory oligonucleotides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Short immunomodulatory oligonucleotides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2765015